Rigorous studies are failing to find that anti Interleukin-6 drugs are effective against COVID-19. Other studies are finding that Interleukin-6 levels are not even highly elevated in Covid patients compared to levels in other critically ill patients.
Three such studies, two published in JAMA Internal Medicine and one in the New England Journal of Medicine, found no evidence that a commonly used Interleukin-6 inhibitor, Tocilizumab, a rheumatoid arthritis treatment, reduced the death rates in severely ill coronavirus patients
